Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic ...

Interim data from the IQIRVO ® (elafibranor) ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers and consistent trends in ...

How to know if a supplement is any good – what works and what doesn’t? - These are all the red flags you need to be aware of ...

Future Market Insights (FMI), a premier market research and consulting firm, today announced the publication of its latest ...

The multi-part labels market size is estimated to be worth USD 1.87 billion in 2025 and is anticipated to reach a value of ...

Anavex (AVXL) awaits a key EU ruling on its Alzheimer’s drug. Learn about trial challenges, approval risks, and why a Sell ...

Diseases that primarily affect populations in low- and middle-income countries (LMICs) have a substantial toll on human health. Annually, more than one billion people are affected by a World Health ...

The firm is now offering combined ex vivo drug sensitivity and genomic testing to cancer patients outside the clinical trial setting.

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

A new analysis found that nearly 700 drugs approved for use in the United States depend on chemicals solely produced in China. By Rebecca Robbins For years, Democrats and Republicans have sounded the ...

Early improvements in skin clearance were observed, with significant differences in vIGA-AD response rates as early as week 1 and maintained through week 8 in children with or without atopic ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A/S (NYSE:NVO) announced that the European Medicines Agency’s Committee for ...